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ABSTRACT
Aberrant DNA methylation is a common feature of
neoplastic lesions, and early detection of such
changes may provide powerful mechanistic insights
and biomarkers for carcinogenesis. Here, we investi-
gate dynamic changes in the mouse liver DNA
methylome associated with short (1 day) and pro-
longed (7, 28 and 91 days) exposure to the rodent
liver non-genotoxic carcinogen, phenobarbital (PB).
We find that the distribution of 5mC/5hmC is highly
consistent between untreated individuals of a similar
age; yet, changes during liver maturation in a tran-
scriptionally dependent manner. Following drug
treatment, we identify and validate a series of differ-
entially methylated or hydroxymethylated regions:
exposure results in staged transcriptional responses
with distinct kinetic profiles that strongly correlate
with promoter proximal region 5hmC levels.
Furthermore, reciprocal changes for both 5mC and
5hmC in response to PB suggest that active
demethylation may be taking place at each set of
these loci via a 5hmC intermediate. Finally, we
identify potential early biomarkers for non-genotoxic
carcinogenesis, including several genes aberrantly
expressed in liver cancer. Our work suggests that
5hmC profiling can be used as an indicator of cell
states during organ maturation and drug-induced re-
sponses and provides novel epigenetic signatures for
non-genotoxic carcinogen exposure.
INTRODUCTION
In the mammalian genome, the dinucleotide sequence
CpG is frequently modiﬁed by the addition of a methyl
group to the ﬁfth position of cytosine base to form 5-
methylcytosine (5mC). Sequences modiﬁed in this way
are often associated with the silencing of transposable
elements and gene promoters as well as playing a role in
X-inactivation, tissue speciﬁc gene regulation and the
regulation of imprinted alleles (1–3). In recent years,
there has been intense interest in a second modiﬁed form
of cytosine, that of 5-hydroxymethylcytosine (5hmC)
found in both cultured cells, tissues samples and cancer
(4–17). A consensus view is that 5hmC modiﬁed CpGs are
typically found enriched in the bodies of actively
transcribing genes, are present at enhancer elements and
at a small cohort of regions spanning an annotated
Transcription Start Site (TSS) (8,17,18). The Ten-eleven
translocation 1-3 (Tet1-3) proteins (TET) family of Fe(II)
and a-ketoglutarate-dependent dioxygenases use molecu-
lar oxygen to transfer a hydroxyl group to methylated
cytosine bases to form 5hmC (15,19–22). Furthermore, it
was shown that Tet proteins can oxidize 5mC or 5hmC
further, converting them to 5-formylcytosine (5 fC) and/or
5-carboxylcytosine (5 caC), which are proposed to be
intermediates in a demethylation pathway, which may be
removed through base excision repair mechanisms by
enzymes such as thymine-DNA glycosylase (23–26). The
gradual disappearance of 5hmC, 5 fC and 5 caC in pre-
implantation embryos indicates that DNA methylation
may be removed in part by a replication-dependent
passive loss mechanism (26,27). Erasure of CpG methyla-
tion in PGCs might also occur as a consequence of passive
demethylation during migration and through conversion
to 5hmC as a consequence of TET1 and TET2 activity
(28,29). Disruption of the TET proteins has been
reported to result in much reduced 5hmC levels, a phe-
nomenon also seen during carcinogenesis (30). For
example, knockdown of TET1 in ES cells leads to an
increase in 5mC at TSS regions of its target genes and a
partial decrease in 5hmC at speciﬁc promoters and within
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gene bodies of TET1 target genes (5,7,9), whereas
knockdown of Tet2 in hematopoietic progenitor cells
results in a block of myeloid differentiation possibly
through a failure to activate critical genes in the differen-
tiation pathway (31,32). Conversely, activation of Tet2
target genes in pre-B cells was also seen to accompany
increased promoter hydroxymethylation (33).
The widely used anticonvulsant phenobarbital (PB), is a
well characterized non-genotoxic carcinogen (NGC) used
to investigate the initiation and progression of non-
genotoxic carcinogenesis in the rodent liver, with pro-
longed exposure (28 days) resulting in the mis-regulation
of gene expression of a cohort of genes as well as the
perturbation of both DNA methylation and histone modi-
ﬁcation patterns that ultimately result in tumour forma-
tion (34–38). Typically, PB is believed to exhibit its effects
through the regulation of nuclear receptors, including the
constitutive androstane receptor (CAR), which mediates
the transcriptional regulation of enzymes involved in
response to drug exposure (39). Both DNA and histone
modiﬁcation proﬁles are perturbed over a handful of
strongly PB induced genes in mice receiving PB in their
drinking water every day for 28 days (17). Strikingly, there
appeared to be a reciprocal gain in 5hmC modiﬁed DNA
over the promoter regions, which had lost 5mC,
resembling an active demethylation event via a 5hmC
intermediate.
Here, we expand on this early work by further
investigating the hydroxymethylomes of both control
and PB-treated mice throughout a time course of
PB exposure. In addition, we characterize the individual
variations of 5hmC and 5mC patterns between several
individual mouse livers of a similar age as well as through-
out normal liver development from young mice (aged
30–33 days) through to mature adults 13 weeks later.
Our study highlights the potential use of 5hmC proﬁles
as an identiﬁer of liver developmental stage. Analysis of
the PB-induced epigenetic perturbations present over the
promoter regions of strongly induced genes following both
short (1 day) and long-term (7, 28 and 91 days PB)
exposure hints at active and ongoing demethylation via
a 5hmC intermediate. Combined epigenomic and
transcriptomic approaches identify a set of potential bio-
markers for the progression of non-genotoxic carcino-
genesis, including several genes involved in cell cycle
regulation, DNA damage response as well as a few
with previously reported perturbation in many cancers
including hepatocellular carcinomas (HCC) (40–42).
Overall, this work provides novel insights into the
5-hydroxymethylcytosine patterns of normal mouse
livers and the dynamic changes resulting from tem-
poral (1–91 days) exposure to a tumor-promotor such
as PB.
MATERIALS AND METHODS
Ethics statement
This study was performed in conformity with the Swiss
Animal Welfare Law and speciﬁcally under the Animal
Licenses No. 2345 by ‘Kantonales Veterina¨ramt
Basel-Stadt’ (Cantonal Veterinary Ofﬁce, Basel) and No.
5041 by ‘Kantonales Veterina¨ramt Baselland’ (Cantonal
Veterinary Ofﬁce, Basel Land).
Animal treatment and sample preparation
In all, 29–32 days old male B6C3F1/Crl (C57BL/6
<C3H/He ,) mice were obtained from Charles River
Laboratories (Germany). Animals were allowed to accli-
matise for 5 days before being randomly divided into two
treatment groups of ﬁve animals each. PB [Sigma 04710,
0.05% (w/v) in drinking water] was administered to one
group through ad libitum access to drinking water for
either 1, 7, 28 or 91 days. Mice were checked daily for
activity and behaviour and sacriﬁced on the last day of
dosing for each required time point of interest. Livers were
removed before freezing in liquid nitrogen and 80C
storage.
Puriﬁcation of 5hmC and 5mC enriched DNA fragments
Genomic DNA was extracted from frozen (80C)
ground-up livers and fragmented to range between 300
and 1000 bp in size (Bioruptor, Diagenode) before
immunoprecipitation. For full HmeDIP and MeDIP
protocols, see Thomson et al. (17) and Lempiainen et al.
(34). For Chemical capture 5hmC enrichment (Active
Motif Hydroxymethyl collector Kit), please refer to manu-
facturers’ protocol. Following puriﬁcation, samples were
prepared for microarray analysis by whole genome amp-
liﬁcation using WGA2:GenomePlex Complete Whole
Genome Kit (Sigma). For hmeDIP and meDIP arrays,
ampliﬁed material was sent to Roche Nimblegen
(Iceland) for Cy3 and Cy5 labelling and hybridization
on 2.1 M Deluxe mouse promoter tiling arrays.
Chemical capture enriched DNA was hybridized in
house on 2.1 M whole genome mouse tiling array 2 of 4
(Nimblegen), which contains a proportion of chromo-
somes 4 and 9 and the entirety of chromosomes 5, 6, 7
and 8.
RNA extraction for expression array analysis
RNA was extracted from liver samples and Affymetrix
expression arrays performed following the methods
outlined in earlier work (34).
Bioinformatic techniques
Processing of Nimblegen promoter microarrays
Nimblegen 2.1 M deluxe mouse promoter arrays (mm9
build) contain 2 056 330 unique probes of 50–70 bp in
length with 50 bp spacing distributed over 21 562 tiled
regions spanning 52 016 annotated TSS regions over
20 718 unique genes. Signals for each probe of the 5hmC
enriched samples (Cy5 labelled) were compared with input
samples (Cy3 labelled) to generate log2 (IP/Input) scores
(fold changes). These log2 scores were then normalized
ﬁrst by Loess normalization and then by scale nor-
malization using the Limma package in R/Bioconductor
(43). For all samples, each probe was then mapped to one
of six regions of the genome based on Refseq gene anno-
tations (see Supplementary Figure S7a). Owing to the
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highly reproducible nature of the patterns, average probe
values were calculated for both the control and PB
exposed groups. Subsequent analysis was carried out by
comparing the differences between the mean control and
mean PB data sets at each time point (1, 7, 28 or 91 days)
and were plotted as changes in the log2 probe values in PB
mice relative to control mice.
Deﬁning regions of differential hydroxymethylation
and methylation
A Student’s t-test was carried out on each probe in the ﬁrst
group with respect to the second and the t-statistic
calculated (i.e. t-statistic calculated between ﬁve control
mice and ﬁve PB-exposed mice). Using the t-statistic as
a value of signiﬁcance, regions where at least three
probes in a four probe window contained t-statistic
values in the top 5% of all values generated were
deemed signiﬁcantly differentially modiﬁed [termed differ-
entially methylated or hydroxymethylated regions
(dHMRs and dMRs)]. In addition, all hyper peak
probes are found to contain t-statistic scores >3,
whereas hypo probe scores are all below 3. By
contrast, the mean value of the t-statistics in the entire
data sets is found to be heavily centred on zero. These
peak probes were then mapped to genomic coordinates
based on the criteria set in Supplementary Figure S7a).
Affymetrix gene expression analysis
Affymetrix gene expression data sets were normalized with
RMA (44). The P-value for the log2 fold change was
calculated with the R/Bioconductor LIMMA package
using a moderated t-statistic. The expression changes fol-
lowing PB exposure were represented as log2 fold change
expression relative to the control mice.
Sliding window analysis of DNA modiﬁcations
Sliding windows of hmC and 5mC proﬁles were
characterized over strongly induced genes (>log2
1.5-fold) at each time point of PB dosing. Sliding
window analysis was carried out using tools on the
University of Edinburgh Wellcome Trust Centre for Cell
biology Galaxy server. Sliding window analysis plots the
average signal taken from a data ﬁles of interest (e.g. mean
5hmC normal probe values) and slides across regions of
interest (chromosome, start, stop) in user-deﬁned steps (in
bp). Sliding window analysis was carried out using a
window size of 200 bp and with a step size of 50 bp and
average signals plotted.
Heat map analysis of PB driven 5hmC perturbation
Average changes to promoter proximal region (PPR)
5hmC or 5mC levels following PB exposure were
calculated for each of ﬁve drug-treated mice versus the
average data set of control mice. Differences in each
mark were calculated by subtracting the log2 score for
each probe in the PB mouse versus the average of the
control mice (n=5). The top 100 PPRs were selected
based on the total delta from control across all ﬁve
mice. Heat maps were drawn using R with colours
taken using the Colour Brewer package (‘RdYlBu’)
ranging from values of 1 to +1 with a 0.4 interval.
Hundred random PPRs were generated and plotted along-
side the PPRs gaining and losing each mark.
Dendrogram clustering of 5hmC and 5mC patterns
Clustering of samples based off of their DNA modiﬁca-
tion samples was calculated from 500 000 random probes
(24.3% total unique probes on array). Dendrogram plots
were carried out using R, and distances were calculated
through both Euclidian and Ward methods.
Uniprot tissue annotation database (‘UP-Tissue’)
expression analysis
Fisher Exact P-values were calculated for the sets of genes
containing either a PPR dHMR or dMR using the
Uniprot tissue annotation database (‘UP-Tissue’)
analysis tool on the DAVID bioinformatic database
website (http://david.abcc.ncifcrf.gov), which plots the
tissues in which sets of genes are typically found to be
expressed (low P-value=expression is highly correlated
to the tissue).
Analysis of enhancer elements
Probes on our array, which correspond to regions deﬁned as
liver enhancers by Shen et al. (45), were taken and crossed to
our 5hmC and 5mC data sets. Nearest genes to an enhancer
element were calculated by using the ‘operate on genomic
intervals’ function on the University of Edinburgh
Wellcome Trust Centre for Cell biology Galaxy server
relative to mouse genome build mm9 gene coordinates.
q-PCR validation of array results
Standard quantitative or real time PCR (qPCR) analysis
was carried out on a Roche Lightcycler480 qPCR machine
(Roche). A list of primers is available in Supplementary
Table S6.
Access to data sets
All 5hmC, 5mC and expression data sets are available on
GEO under the super-series accession number Series
GSE40540.
RESULTS
Global liver 5-hydroxymethylome patterns are highly
conserved between individuals
We ﬁrst set out to fully characterize the 5mC and 5hmC
patterns in normal control liver over the same time course of
PB dosing (13 weeks total). During this period, the livers of
young mice (30–33 days old) continue to mature allowing us
to also study any associated epigenetic changes. To study
the 5hmC and 5mC patterns in the liver, we enriched
for DNA fragments containing either mark using
antibodies speciﬁc for either 5hmC (Hydroxymethyl-DNA
immunoprecipitation; HmeDIP) or 5mC (Methyl-DNA
immunoprecipitation; MeDIP) from a group of mice of
aged 30–33 days old (n=5, see ‘Materials and Methods’
section). The enriched material was then mapped back to
the genome through hybridization to high density promoter
microarrays (Nimblegen 2.1 Million probe Deluxe promoter
array, Figure 1a), which allow us to investigate the
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promoter regions of a large number of mice. The advantages
of the promoter array strategy that we used is that the high
density (2.1 million probes) enabled us to visualize changes
to both 5mC and 5hmC marks following PB exposure at
promoter-associated regions in addition to regions 8kb
upstream and 3kb downstream of annotated transcriptional
start sites. An important point is that we were in a position
to compare multiple samples (ﬁve mice per time point; both
control and drug exposed) to investigate individual vari-
ation between liver 5-hydroxymethylomes. The availability
of multiple sample analysis with this array method also
provides for a signiﬁcant statistical power to this study; in
total, there are 120 data sets (80 DNA modiﬁcations and 40
expression arrays) in this study.
We initially set out to investigate if the liver 5mC and
5hmC patterns differ between individual mice of a similar
age. Overall, Pearson correlations of the individual log2
probe intensity values on the array between each liver
sample (ages 30–33 days) were high for the 5hmC
patterns between all individual livers (average correlation
value of 0.88±0.01; (Figure 1b and Supplementary Table
S1). In all, 5mC levels also exhibit signiﬁcant Pearson cor-
relation values for all probes between individuals (average
correlation value 0.69±0.064), albeit the patterns are less
well conserved than 5hmC. This is likely to be in part due
to cited issues with CpG density dependant binding of the
5mC antibody (46–49).
Visualization of these data sets further highlights the
highly conserved nature of the hydroxymethylome and
methylome between individual livers (Figure 1c and
Supplementary Figure S1); however, to test this further,
we set about deﬁning regions of signiﬁcant epigenetic
change, which occur between the ﬁve mice aged 30–33
days old (dHMRs and dMRs). In brief, this was based
on scoring each probe based on its departure from its
notional value as well as its standard error (the t-statistic),
followed by grouping signiﬁcantly changing adjacent
probes into dHMRs and dMRs (see ‘Materials
and Methods’ section). Globally, there were very
few regions, which exhibited a strong change in
either hydroxymethylation (117 hyper-dHMRs, 51 hypo-
dHMRs) or methylation (92 hyper-dMRs, 84 hypo-
dMRs) across the control group of animals aged 30–33
days (Supplementary Table S2). Additionally, only a
handful of the differentially methylated and/or
hydroxymethylated regions were found to occur within
1kb of an annotated gene transcriptional start site
(deﬁned as PPRs) in at least one of the mice. Indeed,
only seven such PPRs were found to contain a dMR in at
least one of the mice (four hyper, three hypo), and just one
was found to contain an associated dHMR (Supplementary
Table S2). Together, these results highlight global and
promoter speciﬁc conservation of hydroxymethylation
patterns, and to a lesser extent, methylation patterns in
the livers of mice at a similar juvenile stage.
5hmC patterns during late stage liver maturation
We then turned our attention to investigating the changes
to the hydroxymethylome and methylome during a
13-week period of late stage liver maturation. Liver mass
is known to increase 3-fold between the day of birth
(19 days postcoitus) to postnatal day 9, rapid cellular pro-
liferation can be observed up to day 20, but by postnatal
day 30, mouse livers are histologically identical to livers of
mice at 3 months of age (50,51). At this point, the devel-
opmental patterns of gene expression of many liver
speciﬁc genes are stably established (52); however, it is
believed that liver maturation still occurs over the follow-
ing weeks. To test this further and to study the epigenetic
events associated with late stage liver maturation, we
studied the changes to liver 5hmC and 5mC patterns in
young mice aged 30–33 days through to those aged 13
weeks (91 days) later. Interestingly, global 5hmC
patterns are sufﬁcient to stratify the young livers from
those 91 days later in their maturation (Figure 1d),
which is in agreement with previous studies highlighting
5hmC as an identiﬁer of tissue and cell state (16,17). In
contrast to 5hmC, global 5mC patterns alone were unable
to fully separate the juvenile and mature livers from each
other (Supplementary Figure S2).
Using the same approach described earlier in the text,
we ﬁnd a large number of differential hydroxymethylation
(dHMRs) and methylation (dMRs) events occur during 91
days of liver maturation. Globally, we ﬁnd many more
changes occur in the hydroxymethylome (15052; 6775
hypo- and 8277 hyper-) compared with the methylome
(2484; 716 hypo- and 1768 hyper-), indicating that 5hmC
is more dynamic through maturation than its more studied
5mC counterpart (Figure 1e). This is true both for the
number of differential hydroxymethylated and methylated
regions genome wide, over annotated enhancer elements,
as well as a number of genes, which gain or lose either
mark over their PPRs (Figure 1e and Supplementary
Table S3). It has been reported that 5hmC can mark
enhancer elements in both human and mouse cell lines
(8,12) as well as in the mouse liver (17). Although 5hmC
enrichment at enhancers has been proposed to act as an
early event of enhancer activation based on the analysis of
select histone modiﬁcations (8,12), the relationship
between gene expression changes at nearby genes has
not been tested. Here, we investigated the levels of both
5hmC and 5mC over liver enhancer elements [reported by
(45)] and relate these to the expression levels of nearby
genes during 13 week liver maturation. From this
analysis, we ﬁnd that enhancers remain enriched for
5hmC and depleted for 5mC in a manner, which is inde-
pendent of the transcriptional activity of the nearest gene
(Supplementary Figure S3). Further, to this, we ﬁnd that
although a number of enhancer elements contain a dHMR
(n=145) or dMR (n=75) during the 13 weeks of
liver maturation (Figure 1e), there is no correlation
to the transcriptional activity of nearby genes
(Supplementary Figure S4).Taken together, these results
argue that the epigenetic landscape over enhancer
elements (enrichment of 5hmC, depletion of 5mC) is inde-
pendent of the transcriptional activity of the nearby genes
over the period studied.
As a number of genes were found to contain a dHMR
and/or dMR between the young and mature (+91 day)
livers, we set out to investigate the relationships be-
tween the expression of these genes and their PPR
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Figure 1. Global 5hmC and 5mC patterns are conserved between individuals of a similar age but changes throughout liver maturation. (a) Overview
of experimental strategy for the identiﬁcation OF PB-induced epigenetic and transcriptomic perturbations in liver tissue from control and related PB-
treated B6C3F1 male mice (+1,+7,+28 and+91 days dosing). In all, 5hmC and 5mC proﬁles were analysed following antibody based puriﬁcation
techniques (hydroxymethyl-DNA immunoprecipitation: hmeDIP and methyl-DNA immunoprecipitation: meDIP) by promoter microarrays and
veriﬁed by qPCR. The transcriptomes of control and PB-treated livers was investigated by parallel expression microarrays. (b) Global liver 5hmC
and 5mC patterns are similar between animals of the same age (30–33 days old; ‘day 1 mice’). Scatter plots of log2 values for all probes on the array
comparing correlations between ﬁve individual livers and the average of all ﬁve. Correlation values are displayed at the bottom right of each plot in
red. (c) Visualization of 5hmC (purple) and 5mC (red) patterns across the indicated regions in individual livers from mice aged 30–33 days old (‘day 1
mice’). Boxed regions are expanded to reveal the reproducible nature of the DNA modiﬁcation proﬁling. Data are represented by normalized log2
scores for all probes across this region. Annotated Refseq genes are represented below as black bars including gene structures. (d) In all, 5hmC
patterns are sufﬁcient to cluster juvenile mouse livers from mature mouse livers. Dendrogram plot analysis clustered by both Euclidian and Ward
methods (see ‘Materials and Methods’ section). (e) A large number of regions of differential hydroxymethylation (dHMRs) and methylation (dMRs)
occur during 13 week liver maturation (i). In addition to occurring over a number of enhancer elements (ii), a subset of genes is also found to contain
either a dHMR or dMR over their PPRs (iii). Regions gaining a mark (‘hyper-’) are represented by yellow bars, whereas losses (‘hypo-’) are blue.
(f) Plot of P-values for tissue expression levels in genes containing a dHMR. Analysis carried out using the ‘UP_Tissue’ DAVID analysis tool (see
‘Materials and Methods’ section). (g) Boxplot of genes containing a dHMRs/dMRs reveal associated transcriptional changes during 13-week liver
maturation. Genes with hyper-dHMRs are signiﬁcantly elevated in their expression versus those with a 91 day hypo-dHMR, (i) whereas the
relationship with 5mC is the opposite. (ii) **P-value< 0.005, *P-value< 0.05. ‘Hyper-’ events=yellow, ‘hypo-’ events=blue.
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modiﬁcation level. Although GO-term analysis failed to
highlight any particular class of genes, analysis of tissue
expression patterns using the Uniprot tissue annotation
database reveals a signiﬁcant enrichment for dHMRs
over the promoters of genes, which are typically expressed
in the liver (P-value 7.9E7, Figure 1f). As gene expression
data already existed for the same mice from earlier studies
(53), we were able to relate the changes in expression
occurring throughout liver maturation (for juvenile mice
30–33 days and older mice 91 days later) to changes in
promoter DNA modiﬁcations. Typically, genes containing
a gain of PPR 5hmC in the mature mice (‘91 day hyper-
dHMR’) were found to exhibit an increase in gene expres-
sion when compared with genes containing a loss of PPR
5hmC (Figure 1g, Willcox P-values <0.005). Inversely,
genes losing 5mC over their PPRs in the mature mice
were seen to have a small but signiﬁcant increase in their
gene expression change to genes which had gained PPR
5mC (Figure 1g, Willcox P-values <0.05).
Together, these results highlight the fact that 5hmC in
particular is a useful indicator of cell state throughout
liver maturation; ﬁrst, owing to the highly reproducible
distribution of the mark between multiple individuals of
a similar age as well as its relationship with associated
gene expression events, which take place during liver
maturation.
PB mediated perturbations to the liver hydroxymethylome
are highly reproducible between individuals
We have previously reported that 28-day exposure to the
drug PB results in the induction of a subset of genes,
which also show reciprocal changes in both 5hmC and
5mC levels over a subset of promoters (17,34). Here, we
expand on this work by investigating temporal dependent
changes to the methylome and the hydroxymethylome fol-
lowing both short term (+1 day) and longer term PB
exposure (+7, 28 and 91 days PB) to better understand
the dynamics of observed epigenetic changes in response
to the drug. Furthermore, as prolonged PB exposure has
been shown to promote tumour formation in the mouse
liver, stable changes in both gene expression and DNA
modiﬁcation patterns over candidate biomarkers follow-
ing longer-term PB exposure may serve to better under-
stand this progression to a cancerous state (54).
Focussing initially on mice who had received short term
(1 day) doses of the drug, we found that the induced per-
turbations to the hydroxymethylome were not random
and were instead largely reproducible between multiple
liver samples (Figure 2a). This was not true for 5mC,
which revealed varying levels of perturbations following
the initial 1 day PB exposure (Supplementary Figure S5).
Following this result, we tested whether the DNA modi-
ﬁcation patterns were sufﬁciently perturbed on PB
exposure to allow for independent clustering of liver
samples. Similar to the clustering of 5hmC patterns
during liver maturation (Figure 1d), the 5hmC patterns
of both short- (1 day) and long-term (91 day) drug-
exposed mice were found to be more similar to one
another than to their control counterparts
(Figure 2b).Global perturbations to the 5mC patterns
were not able to distinguish drug treated from control
livers following short-term PB exposure (Supplementary
Figure S6). Once more, this may be in part due to tech-
nical issues with the antibody (46–49) but may also be due
to the relative abundance of the 5mC modiﬁcation
through the genome, which is thought to contribute to a
far greater proportion of cytosine bases than 5hmC
(55,56). However, clustering of livers receiving longer
doses PB (91 days) based on global 5mC patterns could
better separate drug exposed mice from the relevant
control set (Supplementary Figure S6). One possible ex-
planation for such a result is that 5mC is thought to be a
somewhat stable epigenetic modiﬁcation when compared
with 5hmC. This may represent a requirement for long-
term drug exposure to strongly perturb ‘locked down’
5mC levels, whereas the more dynamic 5hmC modiﬁca-
tion can be rapidly perturbed.
Long-term PB exposure results in exacerbated
epigenetic perturbation
Following the observation that the PB driven perturb-
ations were reproducible between individuals, we set out
to better characterize the dynamic changes to the
epigenome, which occur on prolonged PB exposure.
First, focussing on the epigenomes of livers exposed to
short-term PB dosing, we found that many changes had
already occurred in this short time frame inferring that
epigenetic changes can occur rapidly in response to a
drug or external stimulus. Following this short dose of
PB, we found 6009 regions of differential hydroxyme-
thylation (dHRMs: 3258 hyper, 2751 hypo) and 1604
methylation (dMRs: 1064 hyper, 540 hypo), respectively,
between drug-exposed and control mice of the same age
(Figure 2c). This is particularly signiﬁcant, as it reveals
that a far greater number of perturbations arise through
drug treatment than is seen to occur naturally between
individual mice (168 total dHMRs in mice aged 30–33
days compared with 6009 dHMRs in mice of the same
age+1 day PB).
Analysis of dHMRs and dMRs, which arise following
longer doses of PB (+7,+28 and+91 days PB treatment,
reveals a continuous increase in the levels of perturbation
with prolonged drug exposure. Similar to the results of the
maturation of the liver in control mice, the hydrox-
ymethylome undergoes a greater change than the
methylome in response to PB, as shown by the higher
number of dHMRs than dMRs at all time points tested
Figure 2c).Globally, we ﬁnd around twice the number of
hyper-dHMRs and dMRs than hypo- events, indicating
that there is an overall detectable gain in both of the modi-
ﬁcations following drug exposure.
Mapping of these dHMRs and dMRs to genomic
features present on our array platform (containing 11 kb
regions surrounding annotated transcriptional start sites
for 20 718 unique genes) reveals that the distribution of
these dHMRs and dMRs is dependent on the length of PB
treatment (Supplementary Figure S7). With prolonged PB
exposure, dHMRs are typically lost from ‘promoter distal’
regions and instead are found in ‘genic’ and ‘promoter
ﬂanking’ sites, whereas dMRs are dynamically
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Figure 2. PB induces dose-dependant reproducible changes to the hydroxymethylome. (a) PB-mediated perturbations to the hydroxymethylome are
reproducible between individuals. Heatmap plots of PB driven changes in the 5hmC signals over the 100 most hyper- and hypo- PB perturbed PPRs
(TSS+/ 1 kb). Average changes in 5hmC levels over 100 random PPRs are also plotted. Changes in PPR 5hmC level are calculated for each liver
(n=5) relative to the average of the control group (n=5). Plots range from  log21 (dark red) to  log2+1 (dark blue). These plots reveal the
reproducible nature of epigenetic perturbations over PPRs strongly perturbed by PB. (b) In all, 5hmC patterns can stratify PB-exposed livers from
control groups following both short (i) and long (ii) doses of the drug. Data sets are clustered by Euclidian and Ward methods (see ‘Materials and
Methods’ section). (c) The numbers of dMRs and dHMRs in the data set vary with prolonged PB exposure. Total numbers of deﬁned regions of
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(continued)
redistributed primarily between promoter distal and genic
regions (Supplementary Figure S7). Analysis of the distri-
bution of PB driven dHMRs and dMRs at enhancer
elements present on the array results in very little
overlap, indicating that that enhancer elements do not
undergo dynamic changes to the DNA modiﬁcation land-
scape following PB exposure (Supplementary Figure S8).
Taken together, these results highlight the fact that
PB-driven epigenetic perturbations to the DNA modiﬁca-
tions are highly dynamic and continue to change with
prolonged drug exposure.
PB induces perturbations to the 5hmC and
5mC patterns over a subset of PPRs
Although it is widely recognized that the levels of 5hmC
are lower at regions surrounding the transcriptional start
sites and elevated in the genic regions throughout
annotated genes (18,30,37,57–59), we previously suggested
that changes to 5hmC over PPRs are functionally linked
to changes in liver gene expression occurring upon 28 days
of PB exposure (17). Here, we investigate the changes to
both the 5hmC and 5mC levels over PPRs in the mouse
liver following short (1 day) and prolonged (7, 28 and 91
days) PB exposure. Although 5hmC levels are typically
low directly over a TSS, we ﬁnd that many genes
contain a dHMR in or around their PPRs spanning and
ﬂanking these TSS regions (Figure 2d, For full list of
genes, see Supplementary Table S4). It also appeared
that the number of genes with either a dHMR or dMR
in a PPR was dependant on the duration of PB dosing
(Figure 2d and e; the Xist gene). At these dHMRs and
dMRs, we ﬁnd that the PB-induced perturbations are
highly reproducible between samples with many exhibiting
a gradual shift in the levels of change in relation to the
length of PB dosing (Figure 2e and Supplementary Figure
S9). Therefore, exposure to the drug PB can lead to rapid
changes in 5hmC and 5mC levels at select promoter loci
following transient exposure to a NGC (1 day PB), which
are intensiﬁed following longer periods (7–91 day) of drug
dosing.
Validation of dHMRs and dMRs reveals strength of
hmeDIP-array analysis
Following the identiﬁcation of PB-mediated dHMRs and
dMRs, we set out to independently validate the results of
the array analysis on samples, which had received both a
short (1 day) and long-term (+91 day) drug doses. qPCR
validation was initially carried out on HmeDIP and
meDIP enriched material, and in each case, the regions
deﬁned as losing or gaining either mark were successfully
validated using this technique (Figure 2f–i and
Supplementary Figure S10). Although the 5hmC
antibody used in our hmeDIP has previously been
shown to be highly speciﬁc (17), we also used a recently
described chemical capture technique that relies on the
selective enrichment of biotinylated and glycosylated
5hmC fragments by streptavidin beads to independently
enrich for fragments of DNA containing the 5hmC mark
(18) and then follow this by qPCR over the previously
identiﬁed dHMRs (Figure 2f–ii). The results of this
analysis complement those of the hmeDIP-qPCR experi-
ments, once more validating the results of the microarrays.
Finally, we couple the chemical capture technique to tiling
microarrays of lower probe density to independently
proﬁle PB mediated changes following long-term
(91 day) drug exposure. In doing so, we ﬁnd that this
new data set parallels our HmeDIP-array results
(Figure 2f–iii and Supplementary Figure S11). Overall,
these independent validations reveal the extent of perturb-
ation to select regions of the epigenome following PB
exposure.
Perturbation of the transcriptome following
long term PB exposure
To study changes to the liver transcriptome following PB
exposure, Affymetrix expression arrays were carried out
on both control and PB treated mice following 1, 7, 28 and
91 days of drug exposure (53). Genes showing strong
responses to PB (>log2 1.5-fold induction) were grouped
into one of ﬁve classes based on their expression dynamics
(Figure 3a and Supplementary Table S5). Genes were ﬁrst
grouped on their relative responsiveness to PB (‘rapid’,
‘slow’, ‘late’ or ‘no response’) and then further classiﬁed
by the retention of this induction; either returning to
control levels at later time points of dosing (‘dynamic’)
or remaining stably over-expressed at later time points
(‘prolonged’). From this classiﬁcation, we found 44
genes that were strongly induced following short (1 day)
PB exposure, which either remained so with prolonged
drug exposure (‘rapid prolonged response’, n=17) or
were seen to return to control levels (‘rapid dynamic
Figure 2. Continued
signiﬁcant 5mC/5hmC change are plotted for each mark against the dosage time. ‘Hyper-’= yellow bars, ‘hypo-’=blue bars. (d) A number of genes
contain an associated promoter proximal dMR/dHMR. (e) Visualization of 5hmC perturbation patterns over a PB-induced dHMR. The average
5hmC proﬁles of 30–33-day-old control mice (purple) are shown with respect to the changes in 5hmC following 1, 7, 28 or 91 days of PB dosing (PB
minus control log2 values per probe; green=gain in 5hmC, red= loss of 5hmC). Annotated Refseq genes are represented below as black bars
including gene structures. A region containing a dHMR is highlighted by a box in the main plot. For this dHMR, average 5hmC changes in ﬁve liver
samples are overlaid on the right in the expanded box for each time point of dosing. Individual changes in 5hmC are represented by light blue plots.
Patterns for the 5hmC change in each mouse (light blue) are superimposed so that darker regions highlight regions of reproducible 5hmC change. All
data are represented by normalized log2 scores for all probes. (f) Independent validation of array deﬁned dHMRs. qPCR validation of dHMRs
carried following the hmeDIP technique used to generate the arrays (i) as well as on an antibody independent chemical capture technique (ii). Data
are plotted as fold change in the percentage of 5hmC enrichment/Input for PB-treated mice versus control mice and plotted on a log2 scale to
represent data accordingly. In all, 5hmC-enriched fragments generated by chemical capture were also analysed by hybridization to a tiling array (iii)
and was found to compliment the perturbations seen in the hmeDIP-array dataset, speciﬁcally over the dynamic Cyp2b10 locus (denoted by * in
validation techniques i, ii and iii). Data are plotted as log2 scores for all probes across this region with annotated Refseq genes represented below as
black bars including gene structures. Scale bar is shown below as black bar.
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response’, n=27). Genes belonging to the former group
likely represent those involved in the turnover and metab-
olism of the drug as was veriﬁed by the fact that many
members of this group are involved in the removal of
xenobiotics from the cell, such as the Cytochrome P450
(Cyp) and Glutathione-S-transferase (Gst) families of
genes. Genes exhibiting delayed yet prolonged induction
following 7 or 28 days PB exposure are likely to be
secondary events in either the removal of drugs from the
liver or may be involved in pre-NGC tumour formation
resulting from prolonged PB exposure. As such, it was
interesting to note that several members of this group
have associated roles in the progression of tumorigen-
esis including the gene Wisp1 (WNT1 inducible
signalling pathway protein 1) and the two imprinted
non-coding RNAs Meg3 (Maternally expressed 3, also
known as Gtl2) and Meg8 (Maternally expressed 8, also
known as Rian). The later of these two genes reside
within the imprinted Dlk1-Dio3 locus; a region of the
genome in which misregulated non-coding transcripts
have been observed in mouse and human HCC (41,53).
Additionally, these transcripts have proposed roles in the
regulation of cellular pluripotency (60,61) as well as being
found to deﬁne a subtype of stem cell-like tumours (41).
Gadd45b, Prom1 and Rad51 are also rapidly induced on
PB exposure. These genes all have proposed roles in
response to DNA damage, regulation of the cell cycle
and maintenance of stem cell state. Their activation in a
temporal manner reinforces earlier studies that report in-
duction of these genes in response to PB (34,53,62,63). As
such, this group may represent a class of genes whose
perturbation may facilitate the progression towards a
tumorigenic state following NGC exposure by creating a
pre-neoplastic foci before subsequent mutational change.
Figure 3. Strongly induced PB genes reveal elevated promoter proximal 5hmC levels around the time of initial induction, which are lost with continu-
ous expression. (a) Exposure to PB results in the strong mis-regulation of a set of genes, which can be clustered on their expression dynamics. Genes
showing strong levels of transcriptomic perturbation (>log2 1.5-fold change) are ﬁrst grouped based on the speed of the PB response: ‘rapid’ (1 day
PB), ‘slow’ (7 and 28 days PB) or ‘late’ (91 days PB). Additionally, these genes were either found to maintain this strong induction (‘prolonged’) or
return to basal levels (‘dynamic’).The majority of genes exhibited no PB response (<log2 0.25–>log2 0.25-fold change, n=8418). The number of
genes in each group is shown above each plot with ﬁve examples from each subset shown to the right. (b) Box plot analysis of the change in either
5hmC levels (top plots) or 5mC levels (lower plots) occurring over the PPRs of genes in each cluster outlined in Figure 3a. Classes are indicated by
roman numerals as in Figure 3a. The dashed line denotes levels of change in either mark over genes exhibiting no PB affect. ** denotes P-
value< 0.005 over un-changes genes at each time point, * P-value< 0.05 over un-changed genes). (c) PB-induced changes to 5mC and 5hmC
patterns at transcriptionally induced genes are highly reciprocal and dynamic. Average changes to the 5mC (solid black) and 5hmC (dashed)
patterns are plotted over the PPRs of strongly induced genes at each time point (>log2 1.5-fold change following PB). Although 5hmC is initially
elevated in promoter ﬂank regions, 5mC remains lost from the entire PPR of induced genes. With continued PB exposure (28 day), both marks are
seen to be lost from promoter ‘core’ regions, whereas at prolonged (91 day) PB exposure, both marks are lost from the entire PPR.
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Finally, we found a small cohort of genes, which are only
strongly induced following 13 weeks of continuous PB
exposure (termed ‘late response’ n=7, Figure 3a). In a
similar manner to the group of genes exhibiting a slow
and prolonged response to PB, these genes are of interest
due to their potential roles in the progression to a tumour
state (54,64). Within this group, we identiﬁed another
Cytochrome P450 gene, Cyp2d12, as well as a tumour sup-
pressor Ndrg1 (N-myc downstream regulated 1) and the
chemokine receptor Cxcr7 both of which have been
shown recently to be strongly induced in both human and
mouse HCC (42,65). Taken together, the expression
changes, which occur during short- and long-term PB
exposure, reveal a series of genes with roles in both the
removal of the drug from the liver as well as the identiﬁca-
tion of potential biomarkers for PB driven tumorigenesis.
Promoter proximal 5hmC levels are related to changes in
gene expression following PB exposure
To investigate whether these changes in gene expression are
related to changes in promoter DNA modiﬁcation status,
we investigated changes to promoter proximal 5hmC and
5mC levels in the ﬁve subclasses of PB induced genes as well
as the un-induced set of genes (Figure 3b). Overall, we ﬁnd
that 5hmC levels are typically signiﬁcantly increased over
PPRs of strongly induced genes around the time of initial
transcriptional activation (P-values< 0.005) with a main-
tenance of this elevated 5hmC found at genes with
prolonged expression (Figure 3b—upper panel; ‘rapid
prolonged’, ‘slow prolonged’ and ‘late’ plots).
Interestingly, in genes whose expression levels are not main-
tained in an elevated state after initial gene activation
(Figure 3b—upper panel; ‘rapid dynamic’ and ‘slow
dynamic’), the levels of 5hmC perturbation follow
changes in the transcriptional activity and do not show a
signiﬁcant elevation over the un-induced genes at later time
points. The relationship between 5mC over PPRs and tran-
scriptional perturbation following PB are less clear than
5hmC; however, 5mC levels are signiﬁcantly reduced at
genes, which show rapid induction following PB exposure
(P-values< 0.05) and to some degree remain lower
with prolonged exposure (Figure 3b—lower; ‘rapid
prolonged’).Taken together, these results highlight the epi-
genetic changes occurring over the promoters of
PB-induced genes and reveal the intimate relationship
between 5hmC levels and gene expression state.
Due to the fact that 5hmC is a derivative of the 5mC
modiﬁcation itself (15,59), we set out to test the relation-
ship between 5hmC and 5mC induced changes over these
PPRs. Plots of the average changes in each modiﬁcation
across the PPRs of strongly induced genes (>log2 1.5-fold
change) at each time point of analysis (+1, 7, 28, 91 days
PB) reveal that the patterns of 5hmC and 5mC change are
both dynamic and reciprocal (Figure 3c). In all, 5mC levels
are found to be rapidly lost following transient (1 day) PB
exposure whilst there is an elevation in 5hmC levels over
the promoter ﬂanking regions. These perturbations appear
to be at their most dynamic following 7 or 28 days of
continuous drug exposure (strong gain of 5hmC/strong
loss of 5mC) before loss of both modiﬁcations following
prolonged (91 day) drug exposure. Due to the proposed
role of 5hmC as a demethylation intermediate, this may
represent a completion of demethylation over these PPRs
following gene induction, which would likely create an
open and accessible region around the promoter that can
facilitate the engagement of the transcriptional machinery
and accessory factors.
Cytochrome P450 family members display rapid and
dynamic epigenetic perturbations following NGC exposure
A common family of genes, which appear both transcrip-
tionally induced as well as routinely epigenetically per-
turbed are that of the cytochrome P450 (Cyp) genes.
The CAR in particular plays an essential role in
PB-induced hepatocarcinogenesis in rodents (66);
however, it is uncertain whether increased cytochrome
P450 enzyme activity itself plays a direct role in tumour
formation (67). The response of several of the Cyp genes
have been widely studied following PB exposure
(34,35,37,68–70), as this family of genes are involved in
the detoxiﬁcation of electrophilic compounds, including
carcinogens (71–73). We previously found that 28 days
of continuous exposure to PB resulted in epigenetic and
transcriptomic perturbations to these Cyp genes (17).
We ﬁnd that many of the Cyp genes are strongly
induced following continuous PB exposure (Figure 3a)
with four members belonging to the ‘rapid prolonged’
response group of genes (Cyp2b10, Cyp2c55, Cyp2b13
and Cyp2g1) and ﬁve more found to be in either the
‘slow’ or ‘late’ response classes (Cyp2c65, Cypc37,
Cypb9, Cyp26a1 and Cypd12; Figure 3a). Due to the
fact that 5hmC shows dynamic and strong perturbations
in response to drug exposure, we investigated the changes
over the PPRs of these genes in each of the ﬁve individual
livers to investigate the reproducibility of epigenetic per-
turbation at these loci. In agreement with our earlier ob-
servations (Figures 1b and c), we ﬁnd that the changes to
the hydroxymethylome are highly conserved between in-
dividuals exposed to PB depending on the length of dosing
(Figure 4a). We also observe that these PPRs undergo a
directional change in the 5hmC patterns depending on the
length of drug dosing. Similar to the results described
earlier (Figure 3c), these Cyp genes initially gain 5hmC
at ﬂanking sites outside of the promoter core region
before progressing to a general loss of the mark, which
appears to originate from the TSS. As described above for
genes strongly induced following long-term PB exposure,
this may represent active demethylation through a 5hmC
intermediate (17).
In agreement with our earlier 28 day focused study
(17), we ﬁnd that the PPRs of the Cyp2b10 gene exhibit
some of the most dramatic perturbations to both the
hydroxymethylation and methylation patterns coupled to
strong PB-mediated induction of expression at all time
points tested. Cyp2b10 mis-expression has also been
observed in a subset of liver tumours that occur after
the initial inducer compound has been withdrawn or
arose in the absence of exposure to PB (66,74,75) and
liver tumours that are glutamine synthetase positive and
mutated in b-catenin show concomitantly elevated
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Cyp2b10 expression (38). Thus, strong and prolonged
upregulation of this gene may be of critical importance
for the progression towards tumorigenesis.
Combined epigenomic and transcriptomic approaches
identify potential biomarkers for the early progression
of non-genotoxic carcinogenesis
Through our combined epigenomic and transcriptomic
analysis, we ﬁnd a series of interesting candidates, which
may be used as biomarkers for the progression of non-
genotoxic carcinogenesis. Candidates were selected based
off of their transcriptional response to PB in addition to
any associated epigenetic perturbations. As pointed out
earlier, many of these have roles in the regulation of the
cell cycle, DNA damage response pathways as well as
tumour suppression (Figure 4b and Supplementary
Figure S12).
One such candidate biomarker is that of the non-coding
RNAMeg3. This gene resides in the imprinted Dlk1/Dio3
locus whose transcripts have been found to be elevated in
many liver tumours as well as in response to PB (53,76).
Furthermore mis-regulation of imprinted genes thought to
be a key event in carcinogenesis (77). Here, we ﬁnd for
Meg3, that the levels of 5hmC associated with this gene
increase with prolonged PB exposure (91 days), particu-
larly at regions surrounding the alternative (downstream)
promoter as well as in the body and 30 end of the gene
(Figure 4b and Supplementary Figure S12). Another can-
didate biomarker is that of the late PB response gene and
tumour suppressor Ndrg1, which exhibits a loss of 5hmC
directly over the TSS and promoter proximal changes in
5hmC levels around the same time with which the gene
becomes strongly induced (91 days PB, Figure 4b and
Supplementary Figure S12). In support of our selection
Figure 4. Analysis of candidate PB exposure biomarkers with potential roles in the progression of tumorigenesis (a). The cytochrome P450 family of
genes reveal reproducibly dynamic levels of perturbation to their promoter hydroxymethylation proﬁles following both short- and long-term PB
exposure. Changes in the patterns of ﬁve PB treated mice (+1 and+91 days PB) relative to the average of the control mice (n=5) are plotted over
the PPRs of a set of strongly induced Cyp genes ( log2 values for each probe over these regions). Patterns for each mouse are superimposed so that
darker regions highlight regions of reproducible 5hmC change. Regions of strong 5hmC gain (>log2 1.5-fold increase) are denoted by green brackets,
whereas red brackets denote regions of strong 5hmC loss (>log2 1.5-fold decrease).Structures of the promoter regions are shown below in blue. (b)
Following PB exposure, perturbations to the 5hmC patterns in a subset of strongly induced genes facilitate the identiﬁcation of candidate biomarkers
for the progression of NGC. Plots show changes in the 5hmC log2 scores at the four time points of PB dosing over six potential biomarkers. Plots
below the zero line indicate net loss of 5hmC following PB exposure (red bars), whereas a gain represents an increase in the modiﬁcation (green bars).
Dashed boxes indicate PPRs (TSS ± 1kb) with an overlapping PPR found at an alternative promoter at the Meg3 locus, which is boxed as one
region. Refseq annotated genes are displayed below with the direction of the gene indicated with an arrow. Asterisk denotes a region downstream of
the Prom1 gene missing from the 28 day data set due to a change in probe locations on the microarrays.
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of this gene as a potential biomarker for NGC progres-
sion, studies have shown Ndrg1 to be highly expressed in
many HCC with associated poor prognosis (65). The same
pattern of promoter proximal 5hmC gain is also noted
for the chemokine receptor Cxcr7 (Figure 4b and
Supplementary Figure S12). There was also a marked
and continual upregulation in the transcriptional activity
of the Prom1 gene, which has roles in the maintenance of
stem cell state and the Wnt signalling pathway geneWisp1
following 1 and 7days of PB exposure, respectively, with
associated increases in the promoter proximal 5hmC levels
at these two genes (Figure 4b). Mis-regulation of the
Wisp1 gene has been previously shown to play an import-
ant role in the progression of malignant transformation in
both mouse and human HCC (78), making it an ideal
candidate biomarker for the progression of NGC follow-
ing PB exposure. As such, these combined epigenomic and
transcriptomic analyses have identiﬁed a candidate set of
biomarkers, which reveal PB response genes, which may
have roles in the progression to a tumour state. Further
work analysing the epigenetic and transcriptomic changes
across these genes in mice with PB-induced tumours may
help to better characterize and validate these loci as bio-
markers for the early progression of NGC.
DISCUSSION
The proposed role of 5hmC as an intermediate in DNA
demethylation pathway has led to a renewed interest in
the study of the DNA methylation modiﬁcation and its
derivatives in both human and mammalian models.
Furthermore, 5hmC patterns have been demonstrated to
change throughout development alongside transcriptional
changes (13). As such, the mark is an ideal identiﬁer of
tissue and cell state. Here, we present a detailed study of
promoter and promoter proximal 5hmC patterns in the
mouse liver between a large number of mice over a
range of ages (30–124 days old). From this analysis on
high density promoter microarrays, we show for the ﬁrst
time that the 5hmC patterns are highly reproducible
between individuals of a similar age, and that these
patterns change as the mouse liver ages. Furthermore,
these changes in promoter 5hmC were seen to correspond
to genes whose expression state also changed during late
liver development.
In addition to the study of normal 5hmC perturbations,
which arise during development, we also study the effects
that both short- and long-term exposure of the widely
studied NGC, PB exhibits on the liver hydroxyme-
thylomes and methylomes. In the rodent liver, the anti-
convulsant PB is widely used as an established model to
study the progression of non-genotoxic carcinogenesis,
with prolonged PB exposure resulting in liver tumour for-
mation (38,54,63,79). As this progression to a tumour
state initially occurs in the absence of genetic perturb-
ation, changes to the epigenome likely underpin this
process. With this in mind, we set out to better understand
PB driven epigenetic perturbations, which may ultimately
result in the progression to a tumorigenic state. Following
the study of the control mice, we show that the 5hmC
patterns alone undergo reproducible levels of perturbation
between individuals exposed to PB. Furthermore, these
perturbations allow the independent clustering of
samples based on PB exposure, which ﬁts with the
notion that 5hmC patterns can be used as a cell state/
tissue identiﬁer (16). We then deﬁned regions of differen-
tial hydroxymethylation and methylation, which we inde-
pendently validated, and then mapped these to the genome
to reveal that the global distribution of these loci change
with prolonged drug exposure. Several studies have previ-
ously investigated the relationships between 5hmC and
transcriptional activity (4,8,9,11,16–18,57,80). We
expand these ﬁndings in this study by analysing select
genes, which respond strongly to PB administration and
ﬁnd that levels of 5hmC are elevated over the PPRs of
strongly induced genes. Furthermore, we show that PPR
5hmC and 5mC patterns are dynamic and reciprocal fol-
lowing both short (12–24 h) and long (91 days) dosing
over strongly induced genes.
As long-term PB exposure is known to induce tumori-
genesis in murine models (54), the genes, which show
delayed and heightened elevation in their gene expression
levels following PB exposure, make ideal candidates as
early biomarkers for the progression of non-genotoxic car-
cinogenesis. Here, we highlight a few such candidates, all
of which have roles in the regulation of the cell cycle,
maintenance of an ES cell state and involvement in
tumour suppression of Wnt signalling pathways. Many
of these genes have already been described as transcrip-
tionally perturbed in liver cancers and human HCC
(41,42,78).
This work allows us to propose a model in which epi-
genetic perturbations occur at PPRs following short- and
long-term PB exposure and in particular how these may
contribute to the progression of tumour formation
(Figure 5). Cells receiving PB will rapidly activate a
series of genes involved in the removal of xenobiotics
such as the cytochrome P450 member Cyp2b10
(68,69,79). As these genes are normally silent, activation
of the gene will ﬁrst rely on the conversion of any
promoter 5mC to non-modiﬁed cytosine through a
5hmC intermediate; an effective example of active
demethylation (Figure 5 - upper). It will be of great
interest to study the epigenetic environment of this
promoter region once the drug has been removed and
the gene silenced once more. Prolonged drug exposure
has been shown to result in tumour formation (54), and
our data suggest that this may be partially due to the
epigenetic perturbation of normal promoter DNA modi-
ﬁcation state and subsequent activation, which may
become constitutive, of a cohort of genes with roles
in cell cycle regulation and progression towards tumori-
genesis (Figures 4b and 5ii). In collaboration with the
Innovative Medicines Initiative MARCAR Consortium
(www.imi-marcar.eu), we are currently evaluating poten-
tial tissue, gender, strain and species (mouse versus rat)
differences in PB-induced perturbations of the DNA
methylome. The mechanistic basis and functional signiﬁ-
cance of early PB-induced changes in speciﬁc DNA
methylation biomarkers is also being explored using
(i) reversibility studies; (ii) PB-promoted liver tumours;
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(iii) transgenic mouse models for key nuclear receptors
[CAR/Pregnane X receptor (PXR); knockout and human-
ized] and cancer signalling pathways (beta-catenin; liver-
speciﬁc knockout); and (iv) liver tumour-sensitive versus
tumour-resistant mouse strains. Furthermore, the sensi-
tivity, speciﬁcity, dose response and reversibility of early
DNA methylation biomarkers is also being explored for a
range of genotoxic and non-genotoxic hepatocarcinogens
with distinct modes of action (e.g. nuclear receptor
mediated versus tissue injury and regeneration).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1–6 and Supplementary Figures
1–12.
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un-modiﬁed cytosines. With long-term NGC exposure, there is also a demethylation of these genes through a 5hmC intermediate pushing them past
an epigenetic ‘point of no return’. On removal of the drug (after long-term dosing), the perturbed epigenetic landscape of these promoters aid in the
constitutive activation of these genes and may lead to neoplasia.
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